Ilia Belotserkovsky

Dr. Ilia Belotserkovsky


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2018
Verified
Book Chapter
Closed access
PDF file
IBIlia Belotserkovsky
Ilia Belotserkovsky
PSPhilippe J. Sansonetti
Philippe J. Sansonetti

13 October 2025 in Applied Microbiology
Verified
Journal Article
Open access
PDF file
IBIlia Belotserkovsky
Ilia Belotserkovsky
CVCecile Vernochet
Cecile Vernochet
MRMaroussia Roelens
Maroussia Roelens
BBBenoît Beitz
Benoît Beitz
BABouthaina Ben Abdallah
Bouthaina Ben Abdallah
CVChristophe Vedrine
Christophe Vedrine
Impairment of the intestinal epithelial barrier, accompanied by local and systemic inflammation, underlies numerous human pathologies, including inflammatory bowel diseases, celiac disease, sepsis, as well as severe acute malnutrition. Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG (LGG®) have been shown in preclinical studies to strengthen the gut epithelial barrier and attenuate inflammation. This study aimed to compare the ability of four commercial strains of B. infantis, LGG, and their combination to mitigate inflammation-mediated epithelial damage using an in vitro immunocompetent intestinal model. A microfluidic mid-throughput platform OrganoPlate® was used to co-culture intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells (PBMCs). Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide (LPS), and probiotic-conditioned media were applied to the apical side of Caco-2 cells to assess effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics significantly protected the epithelium by modulating tight junction protein expression and promoting transcription of homeostatic cytokines, resulting in a “leak-tight” phenotype. These findings indicate that metabolites produced by B. infantis and/or LGG can protect the intestinal epithelium in vitro, warranting further in vivo studies to evaluate the translational relevance of this effect.

27 October 2025 in Applied Microbiology
Verified
Journal Article
Open access
PDF file
NCNaomi Canourgues
Naomi Canourgues
EAEmilie Adicéam
Emilie Adicéam
BBBenoît Beitz
Benoît Beitz
SAScott Xavier Atwell
Scott Xavier Atwell
MRMaroussia Roelens
Maroussia Roelens
IBIlia Belotserkovsky
Ilia Belotserkovsky
The intestinal microbiota plays a crucial role in maintaining epithelial barrier integrity, while its impairment and the resulting inflammation contribute to numerous human pathologies. To preserve intestinal homeostasis, various probiotics are being developed; however, their selection and validation require accessible yet physiologically relevant models. We recently established a high-throughput Gut-on-Chip model comprising human epithelial (Caco-2) cells and peripheral blood mononuclear cells (PBMCs), demonstrating epithelial barrier disruption and pro-inflammatory cytokine secretion upon inflammation induction. The present study aimed to evaluate the feasibility of co-culturing anaerobic members of the human intestinal microbiota within this model and to assess their effects on inflammation-induced epithelial damage. We successfully co-cultured five intestinal anaerobic bacterial species in direct contact with the epithelial monolayer for two days. As proof of concept, we demonstrate that live Bacteroides thetaiotaomicron and its supernatant preserve epithelial barrier integrity and attenuate CCL2 secretion by Caco-2 cells. In contrast, Clostridium scindens did not prevent epithelial damage but suppressed CCL20 secretion, revealing a promising target for future studies. By recapitulating some of the key aspects of intestinal inflammation, we suggest that the current Gut-on-Chip model has potential as an easy-to-use platform for screening next-generation probiotics and live biotherapeutics with homeostatic and immunomodulatory properties.